InDex begins Phase IIb of cobitolimod for UC

InDex Pharmaceuticals Holding AB (SSE:INDEX) began the Phase IIb CONDUCT trial of cobitolimod (DIMS 0150) to treat moderate to severe active ulcerative colitis (UC). Top-line data are expected in 4Q18.

The double-blind, placebo-controlled, European trial will enroll 215 patients with left-sided UC. The trial will evaluate 30, 125 and 250 mg cobitolimod given at baseline and at week 3, and 125 mg cobitolimod given at baseline and weeks 1, 2 and 3. All patients will continue standard of care (SOC) treatment...